Evidence map›Paper›PMID 34183114›Full record

SynthesisSexual health2021

Hepatitis B prevalence association with sexually transmitted infections: a systematic review and meta-analysis.

Elliot Marseille, Aaron M Harris, Hacsi Horvath, Andrea Parriott, Mohsen Malekinejad, Noele P Nelson, Michelle Van Handel, James G Kahn

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Sexual health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elliot MarseilleHealth Strategies International, Oakland CA, USA.
Aaron M HarrisU.S. Centers for Disease Control and Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, USA.
Hacsi HorvathPhilip R. Lee Institute for Health Policy Studies, Global Health Sciences, and Global Health Economics Consortium, University of California, San Francisco CA, USA.
Andrea ParriottPhilip R. Lee Institute for Health Policy Studies and Consortium to Assess Prevention Economics, University of California, San Francisco CA, USA.
Mohsen MalekinejadPhilip R. Lee Institute for Health Policy Studies, Global Health Sciences and Consortium to Assess Prevention Economics, University of California, San Francisco CA, USA.
Noele P NelsonU.S. Centers for Disease Control and Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, USA.
Michelle Van HandelU.S. Centers for Disease Control and Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, USA; and Corresponding author. Email: mvanhandel@cdc.gov.
James G KahnPhilip R. Lee Institute for Health Policy Studies, Global Health Sciences, and Global Health Economics Consortium, University of California, San Francisco CA, USA.

Funding

Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
ECONOMIC ANALYSIS FOR PREVENTION OF DISEASE (EMPoD)U38PS004649 · PS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAHN, JAMES GUSTAVE · 2014 to 2015
$3.0M
NCHHSTP CDC HHS U38 PS004649NIDA NIH HHS R37 DA015612
6 · The paper itself

Abstract

Background Hepatitis B vaccination is recommended for persons with current or past sexually transmitted infections (STI). Our aim is to systematically assess the association of hepatitis B virus (HBV) sero-markers for current or past infection with syphilis, chlamydia, gonorrhoea, or unspecified STIs.

methodsWe conducted a systematic review and meta-analysis. PubMed, Embase, and Web of Science from 1982 to 2018 were searched using medical subject headings (MeSH) terms for HBV, STIs and epidemiology. We included studies conducted in Organisation for Economic Cooperation and Development countries or Latin America that permit the calculation of prevalence ratios (PRs) for HBV and STIs and extracted PRs and counts by HBV and STI status.

resultsOf 3144 identified studies, 43 met inclusion requirements, yielding 72 PRs. We stratified outcomes by HBV sero-markers [surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), combined], STI pathogen (syphilis, gonorrhoea/chlamydia, unspecified), and STI history (current, past) resulting in 18 potential outcome groups, for which results were available for 14. For the four outcome groups related to HBsAg, PR point estimates ranged from 1.65 to 6.76. For the five outcome groups related to anti-HBc, PRs ranged from 1.30 to 1.82; and for the five outcome groups related to combined HBV markers, PRs ranged from 1.15 to 1.89). The median HBsAg prevalence among people with a current or past STI was 4.17; not all studies reported HBsAg. Study settings and populations varied.

conclusionThis review found evidence of association between HBV infection and current or past STIs.

Indexed as

Hepatitis BSexually Transmitted DiseasesSyphilisHepatitis B AntibodiesHumansPrevalenceHepatitis B Antibodies

Identifiers

PMID34183114
PMCPMC8457403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.